Control de factores de riesgo cardiovascular en diabéticos tipo II con aterosclerosis

Thais Pérez Santonja

Thais Pérez Santonja Médico de Familia. CS Galapagar

Palabras clave: Riesgo Cardiovascular, Diabetes tipo 2, Enfermedad cardiovascular, Aterosclerótica, Farmacoterapia

Abstract

Se trata de un estudio de cohortes donde se describe el uso de varias terapias que reducen la morbimortalidad cardiovascular en personas con diabetes mellitus tipo 2 (DM2) y enfermedad cardiovascular aterosclerótica, que sin embargo están siendo infrautilizadas en la práctica clínica.

Citas

Vol 14, Nº 1. 2021. Bradley SM, Adusumalli S, Amin AP, et al; CV-QUIC Collaborators. The Cardiovascular Quality Improvement and Care Innovation Consortium: inception of a multicenter collaborative to improve cardiovascular care. Circ Cardiovasc Qual Outcomes. Doi: https://doi.org/10.1161/CIRCOUTCOMES.120.006753

Vol 144, Nº 1, Págs 74-84. 2021. Nelson AJ, Pagidipati NJ, Aroda VR, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. Doi: https://doi.org/10.1161/CIRCULATIONAHA.121.053766

Vol 129, Nº 25, Págs S1-S45. 2014. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Doi: https://doi.org/10.1161/01.cir.0000437738.63853.7a

Vol 77, Nº 1, Págs 94-102. 2021. Chu CD, Powe NR, McCulloch CE, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria. Hypertension. Doi: https://doi.org/10.1161/HYPERTENSIONAHA.120.16281

Vol 13, Nº 13, Págs 1596-1598. 2020. Nanna MG, Peterson ED. Racial differences in long-term cardiovascular outcomes: the need to move from description to action. JACC Cardiovasc Interv. Doi: https://doi.org/10.1016/j.jcin.2020.05.043